Skip to main content

Table 1 Demographic and past medical history and drugs in RTRs and nonRTRs

From: COVID-19 in renal transplant recipients and general population: a comparative study of clinical, laboratory, and radiological features, severity, and outcome

   Group P
Transplant Pts Non-transplant Pts Total
Count (N %) Count (N %) Count (N %)
Age group Low—50 yrs 11 (45.8) 16 (40.0) 27 (42.2) 0.491
  50—59 yrs 4 (16.7) 12 (30.0) 16 (25.0)  
  60—high yrs 9 (37.5) 12 (30.0) 21 (32.8)  
Age 52.25 ± 12.88 (29.00 – 76.00) 51.58 ± 11.32 (32.0 – 72.0) 51.83 ± 11.83 (29.0 – 76.0)   
Sex Male 17 (70.8) 24 (60.0) 41 (64.1) 0.431
  Female 7 (29.2) 16 (40.0) 23 (35.9)  
HTN   20 (87.0) 16 (41.0) 36 (58.1)  < 0.001
Diabetes   11 (47.8) 12 (30.8) 23 (37.1) 0.179
CVA   1 (4.3) 1 (2.6) 2 (3.2) 0.608
IHD or HF   4 (17.4) 8 (20.5) 12 (19.4) 0.520
DVT   1 (4.3) 0 (0.0) 1 (1.6) 0.371
PTE   0 (0.0) 1 (2.6) 1 (1.6) 0.621
COPD   1 (4.3) 7 (17.9) 8 (12.9) 0.123
Cellcept   24 (12.9)   24 (100.0) -
Cyclosporine   13 (56.5)   13 (56.5)  
Tacrolimus   9 (40.9)   9 (40.9)  
Sirolimus   1 (4.3)   1 (4.3)  
Corticosteroid   23 (95.8) 4 (10.0) 27 (42.2) 0.001
ARB or ACEi   6 (25.0) 13 (34.2) 22 (36.7) 0.444
Atorvastatin   20 (83.3) 13 (34.2) 31 (50.8) 0.001
Warfarin   1 (4.3) 2 (5.3) 3 (4.9) 0.684
HCQ   23 (95.8) 40 (100.0) 63 (98.4) 0.375
Kaletra   17 (70.8) 30 (75.0) 47 (73.4) 0.715
Tamiflu   16 (66.7) 21 (52.5) 37 (57.8) 0.267
Azithromycin   2 (8.3) 8 (20.0) 10 (15.6) 0.189
IVIG   4 (16.7) 0 (0.0) 4 (6.3) 0.017
Gancyclovir   1 (4.2) 0 (0.0) 1 (1.6) 0.375
Ribavirin   2 (8.3) 0 (0.0) 2 (3.1) 0.137
  1. *Mean ± SD (Min—MAX)